Amvuttra Receives Health Insurance Coverage for Transthyretin Amyloidosis
In a significant development for patient access to specialized medicine, Medison Pharma has announced that its treatment for adult transthyretin hereditary amyloid polyneuropathy (ATTR-PN), Amvuttra, is now eligible for health insurance coverage in South Korea. The coverage, which became effective on April 1, 2026, marks a pivotal shift in the availability of this targeted therapy … Read more